Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Craneware full-year revenue set to top expectations

(Sharecast News) - US healthcare management and support specialist Craneware reported a strong full-year sales performance in an update on Thursday, driven by ongoing investment in the Trisus platform and successful partner programmes, resulting in significant returns for its US healthcare provider customers. The AIM-traded firm said it expected revenue to exceed $188m for the 12 months ended 30 June, surpassing the upper end of current market expectations and marking an 8% increase over the prior year.

It also anticipated delivering an adjusted EBITDA of at least $58m, a 6% increase from 2023's $54.9m, maintaining an above-30% EBITDA margin.

The company said it saw growth in annual recurring revenue (ARR), reaching $172m as of 30 June, up from $169m the previous year.

That growth was expected to continue as more sales and partner successes converted to ARR.

Craneware said its strong cash generation enabled continued investment in its future while also significantly reducing its total bank debt to $35.4m, a $40m reduction beyond normal scheduled repayments from 2023's $83m.

It said it returned $12.8m to shareholders through dividends, up from $12.1m in the 2023 financial year, and completed $3.3m in share purchases via its share buyback programme and the employee benefit trust.

Additionally, Craneware said it retained healthy cash reserves of $34.6m as of 30 June, down from $78.5m a year earlier.

Looking ahead, the firm said its strong sales performance underscored the robustness of its Trisus platform, increasing partner success, and its unique market position.

The company said its range of solutions and new market opportunities, accelerated innovation, and exploration of AI-based applications - bolstered by a recently-announced alliance with Microsoft - positioned it to provide valuable insights to its customers.

"The drive for better value in healthcare continues to dominate strategic priorities within the US healthcare market," said chief executive officer Keith Neilson.

"Our positive financial results reflect the demonstrable impact the Craneware Group can make, in helping our customers meet these priorities.

"The exciting growth and expansion opportunities that our new alliance with Microsoft brings to the group, combined with our continued investment in the Trisus platform, the considerable data assets we maintain, and our independence within the US healthcare market mean we are uniquely placed to support all US hospitals."

Craneware said it would announce its results for the year ended 30 June on 3 September.

At 1330 BST, shares in Craneware were up 1.41% at 2,444p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Apollo to buy IGT Gaming and Everi in $6.3bn deal
(Sharecast News) - Apollo Global Management has agreed to buy International Game Technology's gaming and digital business - IGT Gaming - and gambling machines firm Everi Holdings in a $6.3bn cash deal.
3M comfortably beats expectations for Q2 revenue, earnings
(Sharecast News) - American industrial conglomerate 3M announced a strong set of second-quarter results on Friday, comfortably beating market expectations as it narrowed its guidance for the full-year towards the top end of its previous expectations.
Law Debenture delivers 'solid' overall first-half performance
(Sharecast News) - Law Debenture Corporation reported a robust first-half performance in both its investment and independent professional services (IPS) business on Friday.
GCP Infrastructure reports slight decrease in NAV per share
(Sharecast News) - GCP Infrastructure Investments said in an update on Friday that its unaudited net asset value per share was 107.58p as at 30 June, a slight decrease from 107.62p at the end of March.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.